Claro Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Claro Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2	Closed	-$1K	–	950
2018 Q4	$1K	Buy	+2	New	+$763	﹤0.01%	1078

Other funds holding XFOR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claro Advisors's XFOR Position: Q1 2019 in Review

Claro Advisors sold out of X4 Pharmaceuticals (XFOR) in Q1 2019, closing a stake of 2 shares — an estimated $1K sold.

Claro Advisors first reported a position in XFOR in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 29 funds tracked by Wall St. Rank hold XFOR as of Q1 2019.

Claro Advisors reported no remaining X4 Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 2 X4 Pharmaceuticals shares in Q1 2019, an estimated $1K.
Claro Advisors first reported a position in X4 Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claro Advisors's X4 Pharmaceuticals position peaked at $1K in Q4 2018.
29 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.